GlassScriptPhysician profile
Oxana Jourkiv
NPI 1265631071
$11,357.20
in general payments reported to CMS, 2019-2025
31 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $619 · 2021: $1,219 · 2022: $1,433 · 2023: $2,204 · 2024: $2,568 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,091 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,091.01 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,101.46 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $922.75 | 2021-2025 | |
| Lundbeck LLC | $909.98 | 2021-2025 | Rexulti, Brintellix |
| Janssen Pharmaceuticals, INC | $882.88 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $806.20 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $663.20 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $610.30 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $608.42 | 2019-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.41 | 2020-2025 | Caplyta |
| Bausch Health US, LLC | $588.15 | 2021-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $584.31 | 2019-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $486.00 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $463.73 | 2022-2025 | Azstarys, Azstarys |
| Alkermes, INC. | $328.50 | 2021-2025 | Lybalvi, Aristada |
| Shire North American Group INC | $244.86 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $230.49 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $223.39 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $192.55 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $171.97 | 2020-2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $154.95 | 2023-2025 | Auvelity |
| Allergan, INC. | $150.60 | 2019-2020 | |
| Adlon Therapeutics L.P. | $140.93 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $72.47 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $69.41 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $43.16 | 2023-2024 | Loreev Xr |
| Noven Therapeutics, LLC | $20.46 | 2024 | Xelstrym |
| Noven Pharmaceuticals, INC. | $19.72 | 2024 | Xelstrym |
| Tms Neurohealth Centers INC. | $19.26 | 2025 | Tms Neurohealth Centers INC. |
| Vertical Pharmaceuticals, LLC | $17.54 | 2024 | Relexxii |
| Jazz Pharmaceuticals INC. | $16.24 | 2020 | |
| Eisai INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oxana Jourkiv listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.